Mylan teams up with Revance on biosimilar for Botox

Published 6y ago

NEW YORK (Reuters) – Mylan NV on Wednesday struck a licensing agreement with Revance Therapeutics Inc to develop a biosimilar of Allergan Plc’s blockbuster Botox wrinkle treatment. The deal includes an upfront payment of $25 million to Revance​, Mylan said. Re... More »